UC Scientist Receives VA Research Award
Research microbiologist Melanie Cushion, PhD, an expert on the pneumonia-causing fungus Pneumocystis carinii, has received the Veterans Affairs (VA) Research Career Scientist Award from the Department of Veterans Affairs.
A professor in UC's infectious diseases division and project leader of the international Pneumocystis Genome Project, Dr. Cushion currently works at the Cincinnati VA Medical Center studying the role of Pneumocystis as a silent infection in other chronic diseases. The organism especially threatens patients with immune systems weakened by other infections or by chemical agents, such as cancer drugs, and its effect can be frequently lethal.
Pneumocystis has been a mysterious organism since it was first identified in 1912. It began to receive serious scientific attention at the end of World War II, when it caused the death of hundreds of malnourished children in European orphanages.
Understanding the life cycle, metabolism and basic biology of the organism, however, has been hindered by researchers inability to continuously grow the species outside the lung.
Work by Dr. Cushions team and other scientists in sequencing Pneumocystis carinii is now revealing unusual genomic structures and identifying numerous genes involved in encoding cell cycle proteins, information that will lead to a greater understanding and eventual defeat of the organism.
The Research Career Scientist Award provides nearly $400,000 in support over five years and is the highest level award in the career track for nonclinician scientists at the VA. Dr. Cushion is only the third Cincinnati VA Medical Center scientist to receive this honor in the last 20 years.
These funds will be used to continue Dr. Cushions research into Pneumocystis carinii.
Tags
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.
Heavy social media use linked to depression
August 31, 2026
U.S. News and World Report, Yahoo! News, MSN, USA Today and other national media highlight a new study by the University of Cincinnati and Northwestern University that found a correlation between heavy social media use and depression in adults.